Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994082 | 0.85 | CTSK (0.34) | CTSK | |
| SCHEMBL22749258 | 0.83 | CTSK (0.54) | CTSKCA1CA2CA7 | |
| SCHEMBL806058 | 0.83 | CTSK (0.54) | CTSKCA1CA2CA7 | |
| SCHEMBL8135670 | 0.82 | CTSK (0.38) | CTSKCA1CA2CA7 | |
| SCHEMBL23253063 | 0.81 | TSHR (0.31) | CA1CA2CA7 | |
| SCHEMBL20468983 | 0.80 | CTSK (0.33) | CTSK | |
| SCHEMBL10170123 | 0.80 | LMNA (0.39) | CTSK | |
| SCHEMBL8300175 | 0.80 | CTSK (0.37) | CTSKCA1CA2CA7 | |
| SCHEMBL8300173 | 0.77 | SMN1; SMN2 (0.44) | CTSKCA1CA2CA7 | |
| SCHEMBL12140942 | 0.77 | CTSK (0.38) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018145021-A1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| US-20120115918-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110195940-A1 | Protease Inhibitors Having Enhanced Features | NEKTAR THERAPEUTICS (CA) | 2011-08-11 | — | — | US | disclosed |
| EP-2340830-A2 | Hepatitis C Virus Inhibitors | Bristol-Myers Squibb Company (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20110071093-A1 | Novel Reagents | NEKTAR THERAPEUTICS (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2010144869-A2 | PROTEASE INHIBITORS | NEKTAR THERAPEUTICS (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010033219-A2 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | NEKTAR THERAPEUTICS (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20090270499-A1 | Process for Synthesizing Atazanavir | OXYRANE (UK) LIMITED (UK) | 2009-10-29 | — | — | US | disclosed |
| WO-2009130534-A1 | PROCESS FOR SYNTHESIZING ATAZANAVIR | OXYRANE (PTY) LTD. (ZA) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071093-A1 | Novel Reagents | DNPEP, NGLY1, COG7 | CTSK 1039/4885CA1 990/4885CA2 3546/4885 |
| US-20120115918-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CTSK 632/4885CA1 4852/4885CA2 4674/4885 |
| US-20110195940-A1 | Protease Inhibitors Having Enhanced Features | CYP3A43, HPN, ANPEP | CTSK 127/4885CA1 3657/4885CA2 4472/4885 |
| US-20090270499-A1 | Process for Synthesizing Atazanavir | SAMHD1, TYMS, COASY | CTSK 1705/4885CA1 4788/4885CA2 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.